Get started
Author

Tarekegn Hiwot

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
2021 · Jordi Diaz-Manera, Priya S Kishnani, et al. · The Lancet Neurology · 185
PDF
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
2021 · Benedikt Schoser, Mark Roberts, et al. · The Lancet Neurology · 129
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks
2023 · Priya S. Kishnani, Jordi Diaz-Manera, et al. · JAMA Neurology · 57
PDF
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)
2024 · Benedikt Schoser, Priya S. Kishnani, et al. · Journal of Neurology · 31
PDF
The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)
2024 · Giancarlo Parenti, Simona Fecarotta, et al. · Orphanet Journal of Rare Diseases · 25
PDF
Subspecialty training in adult inherited metabolic diseases: a call to action for unmet needs
2019 · Fady Hannah-Shmouni, Constantine A Stratakis, et al. · The Lancet Diabetes & Endocrinology · 16
Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study
2020 · Ales Linhart, Gabriela Dostalova, et al. · Molecular Genetics and Metabolism · 8
2025 Consensus Clinical Management Guidelines for Niemann‐Pick Disease Type C
2026 · Tarekegn Hiwot, Forbes D. Porter, et al. · Journal of Inherited Metabolic Disease · 4
Radiofrequency ablation of ventricular tachycardia in Anderson–Fabry disease: a case series
2021 · Mark T Mills, Thomas A Nelson, et al. · European Heart Journal - Case Reports · 3
PDF
Investigating the role of Miglustat in the management of a patient with Tangier Disease
2021 · Tarekegn Hiwot, Andrew Cook · http://isrctn.com/ · 2
Musculoskeletal deformities of Alström syndrome-a review of 55 cases
2025 · Subadra Wanninayake, Richard Paisey, et al. · Orphanet Journal of Rare Diseases · 1
PDF
Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study
2021 · Ales Linhart, Gabriela Dostalova, et al. · Molecular Genetics and Metabolism · 1
6th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities
2019 · Linhart, A, Nicholls, K, et al. · ˜The œNephron journals/Nephron journals · 1
PDF
EP397 - ECE_1506 - Beyond BMI: obesity phenotype with sarcopenia
2026 · Sadaf Ali, Gabriela Da Silva Xavier, et al. · European Journal of Endocrinology
PDF
Premature aging in alstrom syndrome: a model of monogenic syndromic obesity
2025 · Sadaf Ali, Patricia Thomas, et al. · Endocrine Abstracts
Unveiling the metabolic benefits of GLP-1 analogues in alstrom syndrome: implications for monogenic syndromic obesity management
2023 · Sadaf Ali, Richard Paisey, et al. · Endocrine Abstracts
P005: Head-to-head trial of pegunigalsidase alfa vs agalsidase beta in Fabry disease: Phase 3 randomized, double-blind, BALANCE Study 2-year results
2023 · John Bernat, Eric Wallace, et al. · Genetics in Medicine Open
Renal and secondary outcomes 1 year after switching from agalsidase alfa to pegunigalsidase alfa for Fabry disease (the BRIDGE study)
2021 · Deralynn Hughes, Gabriela Dostalova, et al. · Molecular Genetics and Metabolism
Effect of a Melanocortin-4 Receptor (MC4R) Agonist, Setmelanotide, on Obesity and Hyperphagia in Individuals Affected by Alstrom Syndrome
2018 · Joan C. Han, Fred T. Fiedorek, et al. · 57th Annual ESPE
Prevalence of kidney stones and osteoporosis in patients with primary hyperparathyroidism
2018 · Sherwin Criseno, Tarekegn Hiwot, et al. · Endocrine Abstracts
Prevalence of Kidney Stones and Osteoporosis in Patients with Primary Hyperparathyroidism (PHPT)
2017 · Sherwin Criseno, Neil Gittoes, et al. · Endocrine Abstracts
An international, phase 3, switchover study of reveglucosidase alfa (BMN 701) in subjects with late-onset Pompe disease
2015 · B. Schoser, B. Byrne, et al. · Neuromuscular Disorders
Preliminary clinical efficacy and safety of BMN 701, GILT-tagged recombinant human acid alpha glucosidase (rhGAA), in late-onset Pompe disease: results of an extension study
2014 · Barry Byrne, Richard Barohn, et al. · Molecular Genetics and Metabolism
Heterogeneity and causation of organ dysfunction in Alström syndrome
2012 · R Paisey, C Carey, et al. · Cilia
PDF
Works count: 26
Citation count: 463
H-index: 7
I10-index: 6
Year
Topic
Type